INTRODUCTION

Classic CD4
+ regulatory T cells (T regs ) are identified by the intracellular marker Foxp3 (1, 2) . However, targeting classic T regs for treatment in humans is hampered by the expression of Foxp3 and surface T reg markers on activated cells. Other types of T regs have also been described, including T regulatory 1 (Tr1) and T helper 3 cells (Th3) (3, 4) , although they are not as well understood or characterized as classic Foxp3 + T regs . We have been interested in T regs that express transforming growth factor- (TGF-) on their surface forming a complex with latency-associated peptide (LAP), which identifies CD4 + T regs that have been described in the models of oral tolerance and autoimmunity (3, 5, 6) and are increased in cancer. In colorectal cancer (CRC), LAP + CD4 tumor-infiltrating lymphocytes (TILs) are 50-fold more suppressive than FOXP3 + CD4 T cells (7) . In head and neck cancer, LAP is up-regulated in FOXP3 + CD4 T lymphocytes (8) . TGF- is secreted in the tumor microenvironment by different cells and has an important role in dampening the antitumor immune response (9, 10) . In cancer, TGF- controls cell growth, induces angiogenesis and tumor cell invasion, and promotes immunosuppression (11) . LAP and TGF- are translated as one precursor polypeptide from the Tgfb1 gene that undergoes cleavage by furin, which separates the N-terminal LAP protein portion from TGF-. TGF- is then reassembled with LAP to form a small latent complex (SLC) that retains TGF- in its inactive form on the cell surface. The SLC is then deposited on the cell surface bound to the LAP membrane receptor GARP (glycoprotein A repetitions predominant) or embedded in the extracellular matrix (12) (13) (14) . We used anti-LAP antibodies that we developed (15) to investigate LAP targeting as cancer immunotherapy.
RESULTS
Anti-LAP monoclonal antibody decreases tumor growth in models of melanoma, glioblastoma, and colorectal carcinoma
We used a mouse anti-LAP monoclonal antibody (mAb) (15) in orthotopic and flank syngeneic tumor models. Anti-LAP reduced tumor growth in B16 melanoma (Fig. 1A ) and in both intracranial (orthotopic) (Fig. 1, B to E, and fig. S1A) and subcutaneous ( Fig. 1, F and G) glioblastoma (GBM) (GL261) models. Anti-LAP also affected established B16 tumors ( fig. S1B ). In GBM, an early therapeutic effect was observed because only rare tumor cells were observed at 2 weeks, whereas all control mice developed solid tumors by this time (Fig. 1H and fig.  S1C ). In CRC, anti-LAP reduced tumor number in the azoxymethane (AOM)/dextran sulfate sodium (DSS) orthotopic model of spontaneously induced CRC (Fig. 1, I and J, and fig. S1, D and E) and in two subcutaneous CRC models, MC38 and CT26 (Fig. 1 , K to M). We used The Cancer Genome Atlas (TCGA) data set to study the relationship between the expression of the LAP/TGF--encoding gene TGFB1 and its associated genes (THBS1/TSP-1, LRRC32/GARP, HSPA5/GRP78, and LTBP1/2) with cancer patient survival. We found that the relatively high expression of these genes based on z score was associated with poorer patient survival ( Fig. 1N and fig. S2 ).
Anti-LAP decreases LAP + CD4 T cells and blocks the release of TGF-
Potential mechanisms of anti-LAP effects include reduction of LAP + T cells and/or blocking TGF- release from the SLC ( fig. S3A ). Increased numbers of splenic LAP + T cells in animals with B16 melanoma were reduced after anti-LAP treatment ( Fig. 2A and fig. S3 , B and C), as were the frequency of LAP + T cells in the tumor and draining lymph nodes (dLNs) ( Fig. 2A) . Different noncompeting antibodies were used for anti-LAP treatment (clone TW7-28G11) and for measuring LAP + cells (clone TW7-16B4) ( fig. S3D ). To determine whether anti-LAP blocked the release of membrane-bound TGF-, we used P3U1 cells that overexpress the Tgfb1 gene and secrete TGF- when 
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P < 0.0001 P = 0.01 P = 0.039 P < 0.0001 P < 0.0001 P < 0.0001 P = 0.0001 P < 0.0001 P < 0.0001 LAP is activated. Both 16B4 and 28G11 anti-LAP clones reduced the release of TGF- (Fig. 2B) . Thus, anti-LAP decreases LAP + cells and blocks TGF- release from the cell.
LAP + CD4 T cells from tumor-bearing mice have suppressive properties
We measured markers associated with T regs (Foxp3), exhausted T cells (Lag3, PD1, PD-L1, and Tim3), and CD103 in TILs from B16 melanoma mice on both LAP + and LAP − T cells. Expression of these markers was increased on LAP + versus LAP − T cells (Fig. 2C and fig. S3E ). A similar tolerogenic phenotype was observed for LAP + T regs from the dLNs and spleens of tumor-bearing mice (Fig. 2C and fig. S3 , F and G). We also measured gene expression and found that cancer-associated genes, including Lag3, Tigit, and Vcam, were expressed at higher levels in LAP + versus LAP − T cells (Fig. 2D and fig. S4A ). Irf4, which has been shown to promote effector function of T regs (16) , was also overexpressed in LAP + T cells ( fig. S4A ). Using the NanoString PanCancer Immunology code set, we found 480 genes differentially expressed between B16 melanoma and control mice (Fig. 2E ). Among them, genes associated with effector T reg function, such as Aire, Gata3, Irf4, Foxp3, Stat3, Tgfb1, Tgfb2, Entpd1 (CD39), Itgae (CD103), Il10, Gzma, and Gzmb, and cancer-associated T cell markers, such as Havcr2 (Tim3), Ctla4, Tigit, and Lag3, were expressed at a higher level in LAP + T cells in naïve mice. These genes were further up-regulated in LAP + T cells in tumor-bearing mice (Fig. 2E ). On the other hand, genes associated with T cell activation, including Il6ra, Pin1, and Mapk14, were down-regulated in LAP + T cells in tumor-bearing mice (Fig. 2E ). Because Foxp3 is a marker of T regs in mice, we analyzed the relationship between LAP and Foxp3 in B16 tumor-bearing mice. We performed principal components analysis (PCA) on the NanoString-based gene expression data in LAP
− CD4 T cell subsets. We found that PC1 was associated with the variance between Foxp3 + and Foxp3 − generated data sets, whereas PC2 was associated with the variance between LAP + and LAP − generated data sets. Thus, in addition to the differences between Foxp3
+ and Foxp3 
Anti-LAP treatment modulates dendritic cell subsets in the spleen
Antigen-presenting cells play a key role in antitumor immunity. Because anti-LAP blocks the secretion of TGF-, which is known to interfere with the maturation of splenic antigen-presenting cells (17), we investigated anti-LAP on dendritic cells (DCs) in the spleen in the B16 melanoma model. We measured CD11c-Hi/CD11b-Int (subsequently referred to as CD11c-Hi) and CD11c-Int/CD11b-Hi (CD11c-Int) cell subsets. CD11c-Hi cells were increased after anti-LAP treatment, whereas CD11c-Int cells were reduced (Fig. 3, A and B) . We also measured splenic DCs in the GBM model and observed a similar effect (fig. S5, A and B). In GBM, tumors grow slowly, and the effect of anti-LAP on splenic CD11c/CD11b DCs in GBM was observed with long-term anti-LAP treatment (>3 weeks). CD11c-Int cells express higher levels of LAP versus CD11c-Hi cells ( Fig. 3C and fig. S5C ), which suggests that CD11c-Int cells are more tolerogenic. Because the function of these two DC subsets is not well defined, we characterized their inflammatory properties. We found that both major histocompatibility complex II (MHCII) and CD86 were expressed at higher levels in CD11c-Hi versus CD11c-Int cells (Fig. 3D and fig. S5D ). We then sorted these two DC subsets, stimulated them with lipopolysaccharide (LPS) or anti-CD40, and measured cytokine expression. We found that Il10 was expressed at higher levels and Il12 was expressed at lower levels in the CD11c-Int subset (Fig. 3E) , indicating a more tolerogenic phenotype as compared with CD11c-Hi cells. To determine whether these DC subsets affected CD8 T cells, we cocultured them with labeled CD8 + naïve T cells and measured cytokine secretion and growth. We found increased expression of interferon- (IFN-) and tumor necrosis factor- (TNF-) in cells cocultured with the CD11c-Hi subset (Fig. 3F) , demonstrating that CD11c-Hi cells promote an effector phenotype in CD8 + cells. Furthermore, CD11c-Hi cells supported CD8 + T cell survival to a greater extent than the CD11c-Int subset ( Fig. 3G and  fig. S5E ). Last, we found that anti-LAP treatment decreased LAP + CD11c-Int cells ( Fig. 3H and fig. S5F ) and reduced the expression of the tolerance-associated proteins PD-L1 and CD103 in CD11c-Int cells ( Fig. 3I and fig. S5G ). This is presumably secondary to the reduction of TGF- by anti-LAP (Fig. 2B ) because both genes could be up-regulated by TGF- (18, 19) . Thus, anti-LAP increased DCs with a proinflammatory phenotype and decreased DCs with an antiinflammatory phenotype in the spleen. We found that membrane LAP expression was reduced in CD11c + cells in the spleen, dLN, and tumor after anti-LAP treatment (Fig. 3J and fig. S5H ), indicating that anti-LAP may also affect DCs in the tumor microenvironment. We did not identify CD11c/CD11b subsets in the dLN or tumor ( fig. S5I ).
Anti-LAP treatment enhances antitumor adaptive immune responses
To test whether CD8 + T cells were required for the therapeutic effect of anti-LAP, we implanted B16 melanoma in CD8-deficient mice and found that the therapeutic effect of anti-LAP was abolished (Fig. 4A) . Consistent with this, the therapeutic effect of anti-LAP was also reversed in animals treated with anti-CD8 ( fig. S6A) . No difference was observed in CD4-deficient mice ( fig. S6B ). When we analyzed TILs from mice implanted with B16 melanoma, we found an increase in infiltrating CD8 + T cells after anti-LAP treatment, whereas CD4 + T cells did not change (Fig. 4B and fig. S6C ). Similar results were observed in the intracranial GBM model ( fig. S6D ). Intratumoral CD8 + T cells expressed higher levels of the proliferation marker Ki67, the proinflammatory cytokine IFN-, and the degranulation marker CD107 (Fig. 4B and fig. S6E ). Anti-LAP treatment also increased the ratio of CD8 + T cells to Foxp3 + T regs in the tumor in both B16 melanoma and intracranial GL261 GBM models (Fig. 4B and fig. S6 , E and F). We then examined the dLNs and spleens of B16 melanoma-bearing mice. In dLN, anti-LAP enhanced the proliferation of CD8 + T cells, increased the levels of TNF- in CD8 + and CD4 + T lymphocytes, and increased natural killer (NK) cells and the levels of granzyme B they express ( Fig. 4C and fig. S6G ). In the spleen, we observed higher levels of granzyme B, CD107, and ICOS (inducible T cell costimulator) in CD8 + T cells after anti-LAP treatment, demonstrating a stronger effector phenotype of cytotoxic T cells after treatment. In addition, the frequency of NK cells and the expression of granzyme B by NK cells were increased. Furthermore, the CD44 activation marker was up-regulated in CD4 + T cells (Fig. 4D and fig. S6H ). The percentage of LAP + CD8 T cells was very low in the spleen, dLN, and tumor and did not change with anti-LAP treatment ( fig. S6, I and J), suggesting that these cells do not play a substantial role in the antitumor effect of anti-LAP. Together, these results demonstrate that anti-LAP affects adaptive immune responses both systemically and within the tumor, driving them to a more inflammatory phenotype.
Anti-LAP treatment affects tolerogenic CD103
+ CD8 T cells We consistently found a reduction of CD103 + CD8 T cells in both spleens and dLNs after anti-LAP treatment (Fig. 5A ). TGF- plays an important role in the induction of CD103 + CD8 T cells (20) , which may explain why anti-LAP reduces their number. Because the frequency of infiltrating CD103 + CD8 T cells in B16 tumors was very low (fig. S7, A and B), we focused on CD103 + CD8 T cells in the periphery. We measured gene expression in CD103
+ and CD103 − CD8 T cells from the dLNs and spleens of naïve and B16 melanoma-bearing mice using the NanoString PanCancer Immunology code set. We found 171 differentially expressed genes between groups (Fig. 5B) , among them, activation and effector markers, including Cd44, Gzma, Gzmm, Gzmk, Il2rb, Prdm1, Il18r1, Tbx21, Eomes, and Ccr2; these genes were specifically overexpressed in CD103 − CD8 T cells in naïve mice and were further up-regulated in tumor-bearing mice. On the other hand, negative regulators of T cell activation, including Egr3, Ctla4, and Tgfbr2, were higher in CD103 + CD8 T cells. The T reg -associated genes Il2ra, Foxp3, and Rorc (21-23) were up-regulated in CD103 + CD8 T cells in tumorbearing mice. Tumor suppressor genes, such as Erg1 and Rrad, were down-regulated in CD103 + cells from tumor-bearing mice versus naïve mice, whereas oncogenes, such as Plaur and Vcam, were up-regulated, suggesting that the tumor itself may further modulate the CD103 + T cell subset. In the intracranial GBM model, CD103
+ CD8 T cells infiltrate the tumor, and anti-LAP reduced these cells both systemically and in the tumor (fig. S7C) .
To further investigate CD103 + and CD103 − CD8 T cell subsets under naïve versus tumor conditions, we performed PCA on the global gene signature and found differential clustering of CD103 + versus CD103 − CD8 T cell subsets under both naïve and tumor conditions (Fig. 5C ). PC1 mainly accounts for the variance between CD103 + and CD103 − generated data sets, whereas PC2 accounts for the variance between tumor and naïve generated data sets. Thus, CD103 + marks a CD8 T cell population that is different both in naïve mice and under tumor conditions. We then measured protein expression of activation markers IFN-, TNF-, GzmA, CD44, Eomes, interleukin-18 receptor (IL-18R), IL-2RB, IL-2, CD107, and Ly6C on CD103 + versus CD103 − CD8 T cells in the spleens and dLNs of melanoma-bearing mice. We found that CD103 + CD8 cells expressed lower levels of these markers (Fig. 5D and  fig. S7 , D and E). KLRG1 was also decreased in CD103 + CD8 T cells. On the other hand, IL-10, CTLA4, and CD25/IL-2RA were up-regulated in CD103 + CD8 T cells from dLNs, consistent with the regulatory phenotype of CD103 + CD8 T cells. We then found that CD103 + CD8 T cells isolated from either B16 melanoma-bearing or naïve mice suppressed CD8 + T cell proliferation ( representative of three independent experiments). Error bars, means ± SEM. Two-tailed t test (A and D) and one-way ANOVA (F) were used for P value calculations.
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animals that received CD103 + CD8 T cells and smaller tumor growth in animals that received CD103 − CD8 T cells (Fig. 6A and fig. S8A ). (Fig. 6B) . We isolated these cells at the end of the experiment and found that they maintained expression of CD103 and lower levels of proinflammatory genes (Fig. 6B and fig. S8B ). We observed a similar effect when CD103 + or CD103 − CD8 T cells were adoptively transferred from untreated mice (fig. S8C ). To further investigate the role of CD103, we treated B16 melanoma-and MC38 CRC-bearing mice with anti-CD103 antibody, which primarily targets CD103 + CD8 T cells ( fig. S8D ). We Fig. 1N ). Results for low-grade glioma and GBM are shown. Error bars, means ± SEM. Two-way ANOVA (A, C, and E) and two-tailed t test (B and D) were used for P value calculations. P values for the last time points are shown.
found that anti-CD103 treatment reduced tumor growth (Fig. 6C and  fig. S8E ) and was associated with the reduction of CD103 + CD8 T cells (Fig. 6D) . We then asked whether combined targeting of CD103 and LAP would have a synergistic effect; we treated tumor-bearing mice simultaneously with anti-CD103 plus anti-LAP. We did not observe a decrease of B16 tumor growth as compared with single-antibody treatment with either anti-CD103 or anti-LAP (Fig. 6E) . Consistent with our findings, in patients with both high-and low-grade gliomas, high CD103 expression was associated with shorter survival (Fig. 6F) . CD103 is also expressed in CD4 + T regs , which can contribute to a poorer prognosis. To address the potential role of LAP on CD103 + CD8 T cell function, we examined surface LAP expression and found that the frequency of LAP + CD103 + CD8 T cells was very low, and there was no increased LAP expression in CD103 + versus CD103 − CD8 T cells ( fig. S8F ).
Anti-LAP treatment combined with antigen-specific vaccination enhances tumor immunotherapy and improves immune memory
Because anti-LAP enhances the maturation of antigen-presenting cells, we investigated combining anti-LAP with antigen-specific vaccination. We used B16 melanoma cells that express ovalbumin (B16-OVA) and treatment with DCs loaded with OVA (Fig. 7A ). In this model, OVA serves as a tumor-associated antigen. One week after vaccination with OVA-loaded DCs, mice were implanted with B16-OVA and treated with anti-LAP every third day. No mice vaccinated and treated with anti-LAP developed tumors, whereas 60% of mice treated with isotype control (IC) antibody and all mice in the control group developed tumors (Fig. 7B) . We then asked whether anti-LAP affected immune memory after DC vaccination. We used a series of markers for the activation and memory of CD8 + T cells, including IL-7R, KLRG1, CCR7, and CD62L. On the basis of previously reported CD8 + T cell memory markers (24-26), we found an increase of effector memory-like CD8 + T cells in dLNs of anti-LAP-treated mice (Fig. 7, C to G, and fig.  S9A ). Consistent with our results above, IL-7R + CD103
− CD8 T cells were increased in mice treated with anti-LAP (Fig. 7H and fig. S9B ).
We also investigated the intracranial GBM model in which glioma cells expressing OVA (GL261-OVA) were implanted (Fig. 7I) . One week after vaccination with OVA-loaded DCs, mice were implanted with GL261-OVA and treated with anti-LAP. Disease onset was delayed, and on the basis of magnetic resonance imaging (MRI), none of the anti-LAP-treated mice developed tumors (Fig. 7, J and K) . On day 114, we rechallenged mice that did not develop tumors by subcutaneously implanting GL261-OVA and followed them for an additional month. None of these mice developed tumors, indicating that they had developed antigen-specific immunity against the tumor. We investigated the immune response against OVA in surviving mice and found that anti-LAP-treated mice developed increased numbers of both OVA-specific CD8 cells (Fig. 7L ) and memory cells, as measured by IL-7R and CD62L markers (Fig. 7, M and N) . To investigate the contribution of anti-LAP to immune memory, we vaccinated mice with DCs loaded with OVA and treated them with anti-LAP for 4 weeks (Fig. 7O) . One month later, we rechallenged the mice with a small number of subcutaneously injected GL261-OVA cells. Two months later, we analyzed CD8 + T cells and found specific up-regulation of IL-7R + CD44 + CD8 T cells in anti-LAP-treated mice (Fig. 7P and fig. S9C ), indicating that anti-LAP supports antitumor memory. Thus, combination therapy with anti-LAP improved the immune response to antigen-specific DC vaccination and enhanced immune memory.
DISCUSSION
Although targeting T regs is an important avenue to boost tumor immunity, this approach has been limited because of a lack of druggable T reg targets and a lack of specificity for T regs (27, 28) . We found that targeting LAP may be an effective way to affect T regs and boost tumor immunity because the LAP/TGF- complex identifies a subset of highly suppressive T regs that are up-regulated in human malignancies (7, 8, 29) . + T cells (7) . Consistent with this, anti-LAP did not affect Foxp3 + T cell numbers in our studies. Foxp3 can also be transiently expressed in activated effector T cells in humans (30) , and the accumulation of a Foxp3-lo population, represented by non-T regs , correlates with better survival of CRC patients than Foxp3-hi cells (31) . These studies may explain the different roles of T regs in CRC reported by investigators.
We found that CD103 + CD8 T cells have a tolerogenic immune profile, exhibit suppressive properties, and have a tumor-promoting role in vivo as compared with CD103 − CD8 T cells. Anti-LAP treatment reduced CD103 + CD8 T cells, presumably because it decreases bioavailable TGF-, which regulates the generation of CD103 + CD8 T cells (19, 32, 33) . TGF- has been demonstrated to regulate the generation of CD103 + CD8 T cells (19, 32, 33) . Furthermore, we found that direct targeting of CD103 by an anti-CD103 antibody that reduces CD103 + CD8 T cells in mice similar to what we observed with anti-LAP also had a therapeutic effect in the B16 melanoma and MC38 CRC models. Anti-CD103 antibody appears to act systemically in the B16 melanoma model because only a few CD103 + CD8 T cells infiltrate the tumor in this model. Combinatorial treatment with anti-LAP and anti-CD103 did not result in a synergistic therapeutic effect, indicating that the LAP and CD103 pathways overlap. A previous study of anti-CD103 did not show a therapeutic effect in the CT26 model of CRC (34) . Different roles for CD103 + CD8 T cells have been reported. Some studies report increased effector function against cancer cells (20, 32, 35, 36) , whereas others demonstrate that CD103 + CD8 T cells could be regulatory in transplantation models and autoimmunity (37) (38) (39) (40) (41) . Our study supports these latter observations and extends them to cancer. It is possible that CD103 + CD8 T cells kill cancer cells in the tumor environment while systemically suppressing T cell growth. CD103 has been described as a marker of CD4 + regulatory cells and is present in tolerogenic DCs (2, 34, (42) (43) (44) .
LAP is expressed not only in CD4 + T cells but also in CD8 cells,  T cells, NK cells, B cells, and DCs (45) (46) (47) (48) . Thus, the antitumor effect of anti-LAP could be related to multiple targets. DCs play a key role in tumor antigen-specific vaccination, and we found that anti-LAP plus DC vaccination enhanced the antitumor effects of DC vaccination. Immature DCs express higher levels of LAP, and we found that LAP + DCs in humans have suppressive properties (45) . Although we demonstrate the therapeutic efficacy of anti-LAP antibody in a range of models, the models do not always predict responses in humans. Furthermore, the subcutaneous models we studied do not mimic the natural tumor environment in humans. Nonetheless, LAP + cells are increased in human cancer, have a tolerogenic function, and predict poor prognosis in human cancer (7, 8, 29 In summary, in addition to targeting T regs , our results demonstrate a more complex process because anti-LAP also modulates DCs that express surface LAP, blocks TGF-, and decreases tolerogenic CD103 + CD8 T cells ( fig. S10 ). Anti-LAP acts on multiple populations to promote antitumor immunity by increasing the activity of CD8 + T effector cells and enhancing immune memory. Consistent with our findings, LAP and CD103 expression in human cancer is associated with a poorer prognosis, providing an important translational link between our results and human disease and making anti-LAP an attractive candidate for cancer immunotherapy.
MATERIALS AND METHODS
Study design
Our objective was to investigate the therapeutic effect of anti-LAP antibody in models of cancer and characterize its effect on immune function. We used mice and primary cells and cell lines to address immunologic mechanism. Cages were randomly assigned to different treatment groups. Tumor size and weight loss were the major factors for ending data collection. All data were included in analysis, although in rare situations, clear outliers were excluded. Experimental replication is indicated in the figure legends. Although the study was not blinded, some in vivo experiments were performed independently by investigators in other laboratories. Data were collected using methods that provide numerical values [calipers, scales, bioluminescence imaging (BLI) for tumor size measurement, flow cytometer for assessing protein expression or cell proliferation, and real-time polymerase chain reaction (PCR) instrument and nSolver digital analyzer for mRNA expression measurement]. Animal preclinical studies were reported in accordance with the ARRIVE guidelines. /J)-deficient 6-to 8-week-old male mice were purchased from the Jackson Laboratory. Foxp3-green fluorescent protein reporter mice were housed in a conventional specific pathogen-free facility at the Harvard Institutes of Medicine. All experiments were carried out in accordance with guidelines prescribed by the Institutional Animal Care and Use Committee of the Harvard Medical School.
Animals
Antibody treatments
Mice were treated with either anti-LAP or IC mAbs prepared in PBS. Mouse anti-LAP mAbs were isolated from hybridoma generated inhouse. Two clones were used for in vivo treatments: TW7-28G11 (IgG2b) and TW7-16B4 (IgG1). Respective ICs, MPC-11 (IgG2b), MOPC-21 (IgG1), anti-CD103 (clone M290), and anti-PD1 (RMP-1) were purchased from Bio X Cell. As a standard treatment, antibodies (10 mg/kg) were administered intraperitoneally every third day after tumor implantation. In some experiments, mice were treated intraperitoneally with 100 g of anti-CD8 (clone Lyt-3.2; Bio X Cell) antibody, or IC (rat IgG1; HRPN, Bio X Cell) per mouse on days −1, 7, and 14 after B16F10 implantation.
Statistical analysis
Two-sample t test was used to compare two groups, one-way analysis of variance (ANOVA) with Tukey's adjustment for multiple comparisons was used to compare more than two groups, and two-way ANOVA was used to compare two or more groups over time. Survival curves were compared using a log-rank test. A two-sided  level of 0.05 was used for all tests. Analyses were completed using GraphPad Prism version 7.0a. Details of each analysis are included in the source data in the Supplementary Materials.
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